Maria Ribadeneira

1.1k total citations
27 papers, 839 citations indexed

About

Maria Ribadeneira is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Maria Ribadeneira has authored 27 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Genetics. Recurrent topics in Maria Ribadeneira's work include Hemoglobinopathies and Related Disorders (7 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Maria Ribadeneira is often cited by papers focused on Hemoglobinopathies and Related Disorders (7 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Maria Ribadeneira collaborates with scholars based in United States, Canada and Germany. Maria Ribadeneira's co-authors include Kathleen Carroll, Jameson Forster, Liang‐Shang Gan, Yu Li, Patrick Koch, Lida Antonian, Ajay Madan, Karl Zech, Philmore Robertson and Edward L. LeCluyse and has published in prestigious journals such as Nature, Nature Communications and Blood.

In The Last Decade

Maria Ribadeneira

26 papers receiving 810 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Ribadeneira United States 14 265 232 191 124 94 27 839
Ali Tabatabaei United States 14 262 1.0× 47 0.2× 155 0.8× 155 1.3× 34 0.4× 25 641
Elisabeth Greiner United States 14 209 0.8× 60 0.3× 41 0.2× 175 1.4× 97 1.0× 22 518
Phong Nguyen United States 23 539 2.0× 45 0.2× 76 0.4× 106 0.9× 200 2.1× 51 1.2k
Anna Barańczyk‐Kuźma Poland 17 436 1.6× 82 0.4× 144 0.8× 72 0.6× 129 1.4× 76 974
Toshie Kambe Japan 17 373 1.4× 47 0.2× 131 0.7× 131 1.1× 247 2.6× 29 784
Katharina Mertsch Germany 16 245 0.9× 57 0.2× 168 0.9× 73 0.6× 164 1.7× 22 760
M. Lecomte France 15 342 1.3× 61 0.3× 93 0.5× 85 0.7× 102 1.1× 37 982
Toshiya Ogorochi Japan 15 395 1.5× 36 0.2× 220 1.2× 138 1.1× 159 1.7× 15 1.2k
Chizuko Yamamoto Japan 19 301 1.1× 136 0.6× 322 1.7× 122 1.0× 95 1.0× 48 1.1k
Jochen C. Ulzheimer Germany 10 298 1.1× 83 0.4× 772 4.0× 226 1.8× 56 0.6× 11 1.2k

Countries citing papers authored by Maria Ribadeneira

Since Specialization
Citations

This map shows the geographic impact of Maria Ribadeneira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Ribadeneira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Ribadeneira more than expected).

Fields of papers citing papers by Maria Ribadeneira

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Ribadeneira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Ribadeneira. The network helps show where Maria Ribadeneira may publish in the future.

Co-authorship network of co-authors of Maria Ribadeneira

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Ribadeneira. A scholar is included among the top collaborators of Maria Ribadeneira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Ribadeneira. Maria Ribadeneira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saraf, Santosh L., Modupe Idowu, Ifeyinwa Osunkwo, et al.. (2024). Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. Blood Advances. 8(16). 4459–4475. 7 indexed citations
2.
Ericsson, Anna, David J. Richard, Erik Wilker, et al.. (2024). FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Experimental Hematology. 141. 104673–104673. 1 indexed citations
3.
Schroeder, Patricia, Keertik Fulzele, Maria Ribadeneira, et al.. (2022). Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Journal of Pharmacology and Experimental Therapeutics. 380(3). 210–219. 28 indexed citations
4.
Schroeder, Patricia, James Geib, Diamantis G. Konstantinidis, et al.. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 11(5). 654–665. 23 indexed citations
5.
6.
7.
8.
Ribadeneira, Maria, Sylvie M. Guichard, Lili Yao, et al.. (2019). SCIDOT-42. FT-2102 – A POTENT AND SELECTIVE BRAIN PENETRANT INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE. Neuro-Oncology. 21(Supplement_6). vi280–vi280. 1 indexed citations
9.
Friedman, Allyson K., Barbara Juarez, Stacy M. Ku, et al.. (2016). KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nature. 35 indexed citations
10.
Friedman, Allyson K., Barbara Juarez, Stacy M. Ku, et al.. (2016). KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nature Communications. 7(1). 11671–11671. 118 indexed citations
11.
Tobin, Jenny, Courtney Shea, Adaline C. Smith, et al.. (2015). Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats. BMC Pharmacology and Toxicology. 16(S1). 2 indexed citations
12.
Rioux, Nathalie, et al.. (2013). A strategy to reduce biliary clearance in early drug discovery. Journal of Pharmacological and Toxicological Methods. 68(3). 346–348. 1 indexed citations
13.
Rioux, Nathalie, et al.. (2013). A membrane vesicle-based assay to enable prediction of human biliary excretion. Xenobiotica. 43(10). 915–919. 7 indexed citations
14.
Rioux, Nathalie, et al.. (2012). A simplified approach to predict CYP3A-mediated drug–drug interactions at early drug discovery: validation with clinical data. Xenobiotica. 43(7). 592–597. 4 indexed citations
15.
Zhou, Diansong, Maria Sunzel, Maria Ribadeneira, et al.. (2011). A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABAA receptor modulator – an in vitro and in vivo comparison. British Journal of Clinical Pharmacology. 74(1). 98–108. 10 indexed citations
16.
Chen, Xiaotao, Chu‐Biao Xue, Rui‐Qin Liu, et al.. (2007). A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1′ group for the β-amino hydroxamic acid derived TACE inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(7). 1865–1870. 13 indexed citations
17.
Xue, Chu‐Biao, Xiaotao Chen, John Roderick, et al.. (2004). Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(17). 4453–4459. 27 indexed citations
18.
Xue, Chu‐Biao, John Roderick, James J.‐W. Duan, et al.. (2003). Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization. Bioorganic & Medicinal Chemistry Letters. 13(24). 4299–4304. 26 indexed citations
19.
Madan, Ajay, Richard Graham, Kathleen Carroll, et al.. (2003). Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes. Drug Metabolism and Disposition. 31(4). 421–431. 276 indexed citations
20.
Ribadeneira, Maria, Bruce J. Aungst, Charles J. Eyermann, & Shiew‐Mei Huang. (1996). Effects of Structural Modifications on the Intestinal Permeability of Angiotensin II Receptor Antagonists and the Correlation of In Vitro, In Situ, and In Vivo Absorption. Pharmaceutical Research. 13(2). 227–233. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ali Tabatabaei Breakdown of academic impact, for papers by Elisabeth Greiner Breakdown of academic impact, for papers by Phong Nguyen Breakdown of academic impact, for papers by Anna Barańczyk‐Kuźma Breakdown of academic impact, for papers by Toshie Kambe Breakdown of academic impact, for papers by Katharina Mertsch Breakdown of academic impact, for papers by M. Lecomte Breakdown of academic impact, for papers by Toshiya Ogorochi Breakdown of academic impact, for papers by Chizuko Yamamoto Breakdown of academic impact, for papers by Jochen C. Ulzheimer
Rankless by CCL
2026